At a glance
ClinicalIndex Comparison RecordN/ACompleted· 667 enrolled
Drug / intervention
Sorafenib (Nexavar, BAY43-9006) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors
In Brief
An observational study evaluating Sorafenib (Nexavar, BAY43-9006) and Other Multikinase inhibitors for Thyroid Neoplasms. Completed, enrolled 667 participants across 34 sites in 19 countries.
Detailed Summary
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Neoplasms
CountriesAlgeria, Argentina, Brazil, Egypt, France, Germany, Greece, India, Japan, Lebanon, Mexico, Netherlands, Philippines, Russia, Saudi Arabia, Spain, Taiwan, Turkey (Türkiye), United States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartApr 2015
Primary CompletionJun 2020
Study CompletionJul 2020
TodayJul 2026
First PostedDec 1, 2014
Enrollment StartApr 8, 2015
Primary CompletionJun 10, 2020
Study CompletionJul 24, 2020
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 11.6 years ago
Interventions
Sorafenib (Nexavar, BAY43-9006)drug
Patients can get sorafenib at any time during study.
Other Multikinase inhibitorsdrug
Patients can get MKIs at any time during study.